Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease
- PMID: 40455764
- PMCID: PMC12129228
- DOI: 10.1371/journal.pone.0321864
Development of a novel and viable knock-in factor V deficiency murine model: Utility for an ultra-rare disease
Abstract
Factor V deficiency is a congenital coagulation disorder characterized by the absence or malfunction of factor V (FV). The purpose of this study was to develop a viable FV-deficient mouse model using CRISPR/Cas9 technology. A viable pathological model of the disease was not available to develop new therapies. A previous in silico study was performed to select a mutation causing a mild disease phenotype in humans (Thr1898Met missense). Such mutation was replicated in mice by CRISPR-mediated homology directed repair. Following crossing, homozygous individuals were subjected to coagulometry assays, including FV levels, prothrombin time (PT), and activated partial thromboplastin time (aPTT). The in silico study suggested that the mutation destabilizes FV structure of both mouse and human variants, putatively producing a mild phenotype of the disease in mice. Mendelian inheritance was observed in the offspring. No spontaneous signs of blood clotting disturbances, premature deaths or gestational dysfunctions were observed. FV levels in homozygous animals were 24.5% ± 5.1; 39.7 sec ± 2.8; PT was 61.8% ± 6.3; 23.4 sec ± 1.6 (INR = 1.47 ± 0.12); and aPTT was 46.9 sec ± 3.2. A viable FV-deficient mouse model was generated by introducing a missense mutation in FV. The model exhibits a mild phenotype of the disease, akin to that observed in humans.
Copyright: © 2025 De Pablo-Moreno et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
We have read the journal’s policy, and the authors of this manuscript have the following competing interests: This mouse model, deficient in factor V, is protected by Spanish patent (Ref. ES2948817B2). Holders: Complutense University of Madrid, and Superior Council for Scientific Research. Spain. Inventors: The authors of this article. Official Bulletin of Industrial Property (21-02-2024) Volume 2: Inventions. p. 8. Available in: https://sede.oepm.gob.es/bopiweb/descargaPublicaciones/formBusqueda.action. This does not alter the adherence to PLOS ONE policies on sharing data and materials (as detailed online in the guide for authors http://journals.plos.org/plosone/s/competing-interests).
Figures



Similar articles
-
[Severe hereditary coagulation factor V deficiency caused by two novel heterozygous mutations].Zhonghua Xue Ye Xue Za Zhi. 2005 Mar;26(3):129-32. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 15946520 Chinese.
-
Factor V deficiency.Semin Thromb Hemost. 2009 Jun;35(4):382-9. doi: 10.1055/s-0029-1225760. Epub 2009 Jul 13. Semin Thromb Hemost. 2009. PMID: 19598066 Review.
-
Factor V New Brunswick: Ala221Val associated with FV deficiency reproduced in vitro and functionally characterized.Blood. 2003 Aug 15;102(4):1316-22. doi: 10.1182/blood-2003-01-0116. Epub 2003 Apr 24. Blood. 2003. PMID: 12714495
-
Ser234Leu missense mutation in the A1 domain of factor V causing moderate factor V deficiency in a Chinese family.Pathology. 2009;41(6):566-71. doi: 10.1080/00313020903072734. Pathology. 2009. PMID: 19900106
-
Congenital coagulation factor V deficiency with intracranial hemorrhage.J Clin Lab Anal. 2022 Nov;36(11):e24705. doi: 10.1002/jcla.24705. Epub 2022 Sep 20. J Clin Lab Anal. 2022. PMID: 36125894 Free PMC article. Review.
References
-
- The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff (HGMD). cited 11 November 2024 Internet. Available from: http://www.hgmd.cf.ac.uk/ac/index.php.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases